Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.
Status:
Recruiting
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
This is a prospective, biomarker-driven, open-label, clinical trial of osimertinib in
treatment- naïve patients with EGFR mutant NSCLC, to evaluate the efficacy of osimertinib
according to the TP53 mutational status.